Polianta Ltd’s Summit Therapeutics SMMT Stock Holding History

Polianta Ltd’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-74,700	Closed	-$1.31M	–	115
2025 Q4	$1.31M	Hold	74,700	–	–	0.17%	79
2025 Q3	$1.54M	Buy	74,700 +14,100	+23%	+$342K	0.64%	27
2025 Q2	$1.29M	Hold	60,600	–	–	0.56%	46
2025 Q1	$1.17M	Buy	+60,600	New	+$1.22M	0.56%	30

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Polianta Ltd's SMMT Position: Q1 2026 in Review

Polianta Ltd sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 74,700 shares — an estimated $1.31M sold.

Polianta Ltd first reported a position in SMMT in Q1 2025 and held it in 4 quarters. The position peaked at $1.54M in Q3 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

Polianta Ltd reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
Polianta Ltd sold 74,700 Summit Therapeutics shares in Q1 2026, an estimated $1.31M.
Polianta Ltd first reported a position in Summit Therapeutics in Q1 2025 and held it in 4 quarters.
Polianta Ltd's Summit Therapeutics position peaked at $1.54M in Q3 2025.
222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Polianta Ltd's 13F filing for Q1 2026, filed 16 Apr 2026.